IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
#avct on twitter to see thornogson motivations
Enough to do the job Gje.
If too much is just flushed out then that's not great.
Perhaps why Avacta have told us they're working on half-life extension molecutes?
So that it hangs around longer in the body to increase tumour exposure times and likely clinical outcomes.
Molecular size however will have implications on tumour penetration perhaps?
It's complicated, the 'it works' narrative just looks more lame every time they do a presentation, or alter the trial design, or timelines slip or the share price continues to slide.
I'll help you with another question thorn. If you have a body of volume A and a sub-body inside this of volume B. If a liquid substance is injected into body A and it distributes evenly around bodies A and B, and we want the concentration of this substance to be C in body B, what must the concentration of this substance be in A to reach the desired concentration in B?
GSA a side show, agreed. The dilution however, is not. It comes good eventually.
Science is not your strong point is it thorn. Let’s get this straight, are you trying to tell us that the goal here should be to have all the ava6000 cleaved at the tumour site?
Nothing I have posted runs counter to anything the SAB have said or are doing. SAB are now concentrating on guiding CC to choose best Precision candidates for the pipeline that will really surprise us and deliver investors value.
Gemstar...'our clinical proof of concept data in hand since April 2024'....they obvious feel they have enough to get the ball rolling and are continuing to add to the data portfolio. It's not published data but will be in a format they can use for negotiations. I'm sure CC will have made sure it's presented to attract the best ...
Gemstar...'our clinical proof of concept data in hand since April 2024'....they obvious feel they have enough to get the ball rolling and are continuing to add to the data portfolio. It's not published date but will be in a format they can use for negotiations. I'm sure CC will have made sure it's present to attract the best ...
“Clinical data are key to both equity funding as well as commercial deals “
So when is this clinical data likely to be available?
OK let's cut through the noise...
These are the key points for the rest of 2024...without them Avacta will not be able to move forward...it's all about money...1) get DX profitable and sell. 2) Bring on US Institutional investor(s). 3) Get Business Development Deals. As I said before, there is a real sense of urgency now to GET THINGS DONE...
'• Management is focused on bridging funding gap as far as possible with non-dilutive capital
– The Company is in a process to realize value for Dx assets – drive to EBITDA +ve in 2024 and engaging with potential acquirers
– The Company is seeking business development deals in the Therapeutics pipeline with our clinical proof of concept data in hand since April 2024
• Management is also focused on bringing institutional investors into the story, especially from the US, for the
medium- and long-term capital needs
– Clinical data are key to both equity funding as well as commercial deals
– Management has presence at key global congresses designed to foster collaborations (AACR, ASCO, BIO) and clinical proof of concept for the preCISION platform enables
– Board and Executive Team with credibility in the eyes of US specialist healthcare investors, who typically support companies at this stage of their evolution'
I’m not that bothered about GSA to be honest. I own shares at a comfortable level in an ISA. This will either come good or it won’t. I was pleased by the AGM recording as there’s now a strategy in place, ultimately for exit. All this is irrelevant once BP come knocking, tidying up Dx/CLN is just a step in that process.
Christina understands better than most that whilst they do of course need a healthy bank balance what they need even more is a strong and supported share price and for that the 'market' needs convincing that avct now has a management team that has investors' interests at the forefront of their decision making and so for that reason I'm confident this next payment is made in cash... even if it goes back to shares or part payment in shares from October (LD/Dx sale dependent)
When they announce that though is anyone's guess but it'll be timed to have maximum impact.
If GSA decided to buy back in the CLN share sale, there’ll be no pressure. They’ll get out Scott free. Paying in shares would be ace, at a higher SP. Agree on sentiment, but not would be another kick if they do.
“Most must be simply flushed straight through” - yes that’s right, that is what is desired.
I also disagree and hope they pay in shares, keep the cash to keep the bank balance healthy. It’s been calculated by gje, the CLN is nothing worth bothering about. They need cash for Tx, that hasn’t changed. I like the idea of saddling the debt on Dx. Pretty clear Dx divestment conversations have begun anyway, so sort it out. As you’ve said GSA will need to buy so there’s plenty upside pressure to come.
Thorn - how much is required to land in the tumour?
CTSFO your point RE AVA6000 effectively 'disappearing' because it's actually hitting FAP and being cleaved is a good one.
The reality in most patients however is that the percentage of a person's body mass made up of tumour cells will be small, it would take many, many, many circulations of the body for all the bloods circulation to pass past or through this relatively small volume of the total available?
Most must be simply being flushed straight through.
They've measured the 'leaving group' however so must know, and the slide says minutes to hours.
I think it’s pathetic to suggest trolls are short. They are physically, they live under bridges and in sweaty basements. I know they’re all thick, but having a short open at this level is beyond their idiocy shirley. It’s also convenient to blame shorters when near a share price low, like a cuddly blanket to blame evil forces - rather than Alan.
Not noticed how their personalities change, writing styles change, in fact entire personas change. They’re not posting on shares with little to no retail popularity and have you not noticed that every popular share board has a contrarian twat trolling. They’re here for ad traffic. Ignore it and if you can’t bin it.
13.12.2023 AVA 6000 update - presentation - Concentration in blood vs. time following dose - 160 mg/m2 cohort
https://avacta.com/wp-content/uploads/2023/12/AVA6000-Data-Release-13-December.pdf
Sheet 15
Title: AVA6000 Leads to Reduced Concentration and Exposure to Doxorubicin in the Blood - versus time
Reduction in maximum concentration and total exposure
>80% reduction across all dose levels of the maximal concentration (Cmax) and 40-80% reduction in total
exposure (AUC) of released doxorubicin following AVA6000 dosing compared with standard dose doxorubicin.
++++
Does this info assist anyone?
Please like if you agree.
Get paid for their reaction, it's pathetic really to accuse anyone of calling out BS to be paid to reply. Get a grip FFS.
What is clear is Touk is not invested and given the posting volume is surely short. I suspect the FUD will increase as we get into the CLN calculation period. Really hope they pay in cash and we build on up. GSA algo then buys back its shares and we accelerate the increase in share price.
And they get paid for any reaction…
Waste of time telling them, they actually enjoy it too!
Agree ,by replying or reacting you just fuel their agenda
I wondered whether a FAP cascade type process could be used to supercharge AVA6000. If the linker could be attached to FAP itself to disable it until it gets to the TME where it is cleaved to release more FAP and start a cascade process. If AVA6000 was given alongside, the cleavage of AVA 6000 could be very large. I appreciate the same effect might start in the plasma so might not be good but at 2log difference it might. Do other drugs use such an approach?
Thats why its so ridiculous that people are giving the argument so much attention.
Thorn - what levels are good?